Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaki...
April 08 2019 - 8:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, today stated that its
previously announced positive clinical data from the Company’s
Limb-girdle muscular dystrophy (LGMD) Type 2E gene therapy program
has been accepted for a late-breaker oral presentation at the
Muscular Dystrophy Association (MDA) Clinical and Scientific
Conference in Orlando, Fla.
Title: Systemic Gene Transfer
with AAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in
Patients with Limb Girdle Muscular Dystrophy Type 2E (Rodino-Klapac
et al.)
Details: Tuesday, April 16,
4:00-4:15 p.m. ET; Clinical Trials Session; Regency R-S
Louise Rodino-Klapac, Ph.D., Sarepta’s Senior
Vice President of Gene Therapy, will present.
In addition to the late-breaker, six posters
highlighting data from Sarepta’s RNA and gene therapy programs for
Duchenne muscular dystrophy (DMD) and LGMD 2D will be presented
during the Networking & Poster Sessions in the Exhibit Hall on
Monday, April 15, and Tuesday, April 16, 2019.
The oral presentation and posters will be
archived under the events and presentations section of the Sarepta
Therapeutics website at www.sarepta.com for 90 days following
their presentation at MDA.
About Sarepta
Therapeutics
Sarepta is at the forefront of precision genetic
medicine, having built an impressive and competitive position in
Duchenne muscular dystrophy (DMD) and more recently in gene
therapies for 5 Limb-girdle muscular dystrophy diseases (LGMD),
Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related
disorders, totaling over 20 therapies in various stages of
development. The Company’s programs and research focus span several
therapeutic modalities, including RNA, gene therapy and gene
editing. Sarepta is fueled by an audacious but important mission:
to profoundly improve and extend the lives of patients with rare
genetic-based diseases. For more information, please visit
www.sarepta.com.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan,
617-274-4052iestepan@sarepta.com Media:Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024